Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1015001#aggregation> ?p ?o. }
Showing items 1 to 35 of
35
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B604885.
- aggregation creator B604886.
- aggregation creator B604887.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1015001.bibtex.
- aggregation hasFormat 1015001.csv.
- aggregation hasFormat 1015001.dc.
- aggregation hasFormat 1015001.didl.
- aggregation hasFormat 1015001.doc.
- aggregation hasFormat 1015001.json.
- aggregation hasFormat 1015001.mets.
- aggregation hasFormat 1015001.mods.
- aggregation hasFormat 1015001.rdf.
- aggregation hasFormat 1015001.ris.
- aggregation hasFormat 1015001.txt.
- aggregation hasFormat 1015001.xls.
- aggregation hasFormat 1015001.yaml.
- aggregation isPartOf urn:issn:1369-7137.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Optimal tolerability of ultra-low-dose continuous combined 17β-estradiol and norethisterone acetate: laboratory and safety results".
- aggregation abstract "Objective To evaluate the influence of two ultra-low doses of oral continuous combined hormone therapy and placebo on metabolic parameters, and to assess safety endpoints and overall tolerability in healthy postmenopausal women. Design In a subpopulation of the Clinical study on Hormone dose Optimisation In Climacteric symptoms Evaluation (CHOICE) trial, lipids and parameters of glucose metabolism and hemostasis were analyzed in Nordic women (n = 158) at baseline and after 12 and 24 weeks of treatment with 0.5 mg 17 beta-estradiol (E2) + 0.25 mg norethisterone acetate (NETA), 0.5 mg E2 + 0.1 mg NETA or placebo. Adverse events Occurring from the first trial-related activity, whether related or not related to the study me dication, were recorded for the entire population (n = 575) of the trial. The seriousness, relationship to treatment and the reason for withdrawal were reported. Results Both ultra-low-dose combinations were neutral to changes in lipid and lipoprotein, hemostasis parameters and carbohydrate metabolism during the trial. The incidence of serious adverse events was only 1% in respective treatment groups. Adverse events were the reason for withdrawal in only 2% and 6%) of women In the 0.5 mg E2 + 0.25 mg and 0.4 mg NETA groups, and in 8% in the placebo group. No weight gain or change in blood pressure was reported during the trial in ally of the study groups. Conclusion The treatments had neutral effects on metabolic parameters in the study population. Excellent tolerability of both Ultra-low doses resulted in high completion rates.".
- aggregation authorList BK960448.
- aggregation endPage "44".
- aggregation issue "1".
- aggregation startPage "34".
- aggregation volume "13".
- aggregation aggregates 1015005.
- aggregation isDescribedBy 1015001.
- aggregation similarTo 13697130903480706.
- aggregation similarTo LU-1015001.